Intervention Protocol

You have full text access to this OnlineOpen article

Antibiotics for secondary prevention of coronary heart disease

  1. Maria Skoog1,*,
  2. Berit Grevstad1,
  3. Jørn Wetterslev1,
  4. Asbjørn Hróbjartsson2,
  5. Christian Gluud3

Editorial Group: Cochrane Heart Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD003610.pub2

How to Cite

Skoog M, Grevstad B, Wetterslev J, Hróbjartsson A, Gluud C. Antibiotics for secondary prevention of coronary heart disease (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD003610. DOI: 10.1002/14651858.CD003610.pub2.

Author Information

  1. 1

    Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Copenhagen, Denmark

  2. 2

    Rigshospitalet, The Nordic Cochrane Centre, Copenhagen, Denmark

  3. 3

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Maria Skoog, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 28 FEB 2013




  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Description of the condition

Coronary heart disease (CHD) is the narrowing or blockage of the coronary arteries, usually caused by atherosclerosis due to build-up of fatty material and plaque. The Atherosclerotic pathological process in the walls of blood vessels is complex and develops over many years. CHD is the leading cause of death worldwide, particularly in low-middle income and high income countries, with an estimated 3.8 million men and 3.4 million women dying each year (WHO 2004; WHO 2011). Common risk factors of CHD include tobacco use, physical inactivity, overweight and obesity, hypertension, diabetes, hyperlipidaemia, advancing age, gender, and inherited (genetic) disposition (WHO 2011).

Infections may be involved in the pathogenesis of atherosclerosis (Fabricant 1978). It has been suggested that the pathogenic mechanism of the various infectious agents might be an increased inflammatory response seen in connection with infections (Aceti 1996). A number of studies have assessed the association between CHD and various infectious agents, notably Chlamydia pneumoniae (C. pneumoniae), Helicobacter pylori (H. pylori), and cytomegalovirus, but the results are equivocal.

There appears to be an association of C. pneumoniae and CHD based on studies demonstrating the presence of C. pneumoniae in atheromatous plaques (Shor 1992; Kuo 1993; Muhlestein 1996; Ramirez 1996), on retrospective seroepidemiological studies demonstrating an increased amount of antibodies in patients with acute or chronic CHD (Saikku 1988; Leinonen 1990; Thom 1991; Thom 1992; Linnanmaki 1993; Melnick 1993; Patel 1995; Dahlen 1995; Kazar 2005), on a prospective seroepidemiological study (Romano Carratelli 2006) , and on a meta-analysis of seroepidemiological studies (Danesh 1997). However, the results are equivocal and two prospective studies (Ridker 1999; Danesh 2000a; Danesh 2000b, Danesh 2002) and a meta-analysis of prospective seroepidemiological studies (Danesh 2000a; Danesh 2000b, Danesh 2002) could not find any strong association between C. pneumoniae immunoglobulin G nor immunoglobulin A titres and CHD.

Some epidemiological studies have shown a modest association between antibodies to H. pylori and CHD (Danesh 1997), and a recent prospective seroepidemiological study (Lenzi 2006) showed a higher overall prevalence of H. Pylori in patients with CHD. Larger studies and a meta-analysis of prospective studies, however, could not demonstrate any association (Danesh 1998), nor could two prospective studies (Folsom 1998; Roivainen 2000).

A recent meta-analysis on the risk of CHD in relation to cytomegalovirus infection demonstrated an increased in CHD risk for people exposed to cytomegalovirus infection in both prospective studies and retrospective studies (Ji 2012).


Description of the intervention

Antibiotics are of different classes, for example penicillins, macrolides or tetracyclines. A few randomized clinical trials have assessed the effects of macrolide antibiotics given as secondary prevention to patients with CHD and known C. pneumoniae seropositivity (Gupta 1997; Anderson 1999), C. pneumoniae and/or H. pylori seropositivity (Torgano 1999), or unknown antibody status (Gurfinkel 1999; Neumann 2001). The results are equivocal. A statistically significant reduction in the incidence of coronary events in the group receiving antibiotics compared with the group receiving placebo were reported by one trial at 18 months follow-up (Gupta 1997), and at the end of 30 days treatment but not at six months follow-up by another trial (Gurfinkel 1999). Finally, a third trial found no significant difference in coronary events at the end of treatment or at 24 months follow-up (Anderson 1999). The results of these three trials are all limited by the small number of patients included (from 60 to 302). There is a great risk of both false positive responses, i.e. the reduction in the number of events in the antibiotic-treated group occurred by chance, and false negative responses, i.e. the trials were too small and underpowered to demonstrate a clear benefit or harm. Although C. pneumoniae has been the main target and macrolide antibiotics have been the principal antibiotic treatment in most studies, C. pneumoniae is susceptible to a variety of antibiotics of which some have been assessed in randomized trials (Sinisalo 1998). Further, various antibiotic treatments might be used against other bacterial agents that may be associated with atherosclerosis, e.g. H. pylori. Moreover, antibiotics may have general anti-inflammatory effects that could affect the atherosclerotic lesions (Agen 1993).


How the intervention might work

The mechanism by which antibiotics may prevent CHD is not established. It is assumed that it is through an antibacterial activity. However, macrolides also exert anti-inflammatory activity (Agen 1993).


Why it is important to do this review

There have been several attempts to meta-analyze randomized trials assessing antibiotics for secondary prevention of CHD (Andraws 2005; Jespersen 2006; Gluud 2008). Andraws 2005 analyzed 11 trials with 19,217 participants and could not demonstrate a significant benefit. We meta-analyzed 13 trials with 24,063 participants and could not demonstrate benefit or harm, but the estimate showed a relative increase of mortality of 9% in the antibiotics group (Jespersen 2006). When we updated the analysis with 17 trials and 25,271 patients, there was a significant increased mortality of 10% in the patients receiving antibiotics (Gluud 2008). These analyses were not conducted as systematic reviews taking into consideration the risk of systematic errors and the risk of random errors (Wetterslev 2008; Keus 2010; Higgins 2011). In the present systematic review, we will collect and present current evidence of antibiotic treatment given as secondary prevention for CHD.The review will attempt to assess if the efficacy of antibiotics in general and macrolide antibiotics in particular is related to C. pneumoniae, H. pylori, or cytomegalovirus titres.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

To assess the beneficial and harmful effects of antibiotics given as secondary prevention to patients with CHD.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Criteria for considering studies for this review


Types of studies

We will include all secondary prevention randomized clinical trials, irrespective of trial design or setting, blinding, publication status, publication year, or language. we will include unpublished trials if the methodology and the data of the trial can be accessed in written form. We will also include non-randomized studies (e.g. quasi-randomized studies and observational studies) for the assessment of harms. We will use such studies as we identify them, but we will not conduct specific searches to identify them.


Types of participants

Patients with a diagnosis of acute or chronic CHD (i.e. acute or previous myocardial infarction; stable or unstable angina) according to the definitions of the individual trials. We will also include trials with no explicit definitions. Patients can be of any age, sex, and have known or unknown antibody status for C. pneumoniae, H. pylori, and cytomegalovirus.


Types of interventions

Any kind of antibiotics in any dose, rout of administration, or duration versus placebo or no intervention. We will accept collateral experimental interventions if given to both intervention groups of the trial.


Types of outcome measures

We will consider all outcomes at the end of treatment and at the maximum follow-up according to the individual trial.


Primary outcomes

  • All-cause mortality
  • Cardiovascular death (as determined by the included trials)
  • Number of serious adverse events

Serious adverse events, defined according to the ICH guidelines as any event that would increase mortality; was life-threatening; required inpatient hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability; or any important medical event, which may have jeopardized the patient or required intervention to prevent it (ICH-GCP 1997).


Secondary outcomes

  • Quality of life
  • Non-fatal myocardial infarction
  • Unstable angina pectoris
  • Stroke

Any adverse event defined as any untoward medical occurrence in a patient, which did not necessarily have a causal relationship with the treatment, but resulted in a dose reduction or discontinuation of treatment.


Search methods for identification of studies


Electronic searches

We will search the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library.We will supplement this by searches of MEDLINE Ovid, EMBASE Ovid and ISI Web of Science. The preliminary search strategy that is given in Appendix 1 will be used to search MEDLINE and adapted appropriately for use with other databases. The search will include the addition of a standard randomized control trial filter for MEDLINE and EMBASE(Higgins 2011).


Searching other resources

We will search for ongoing trials on:

The reference lists of relevant publications will be checked for any unidentified randomized trials. We will contact authors of included studies, and major pharmaceutical companies, by post or email asking for unpublished randomized trials.

We will apply no language restrictions.


Data collection and analysis


Selection of studies

Two authors (MS, BG) will independently assess trial eligibility without blinding of the trial authors, investigators, institution, source, or results. Disagreements will be resolved by discussion with a third author (CG). we will list excluded trials with the reason for exclusion. Study selection will be displayed in an adapted flow diagram as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher 2009).


Data extraction and management

Two authors (MS, BG) will extract all data independently. Disagreements will be resolved by discussion with a third author (CG or JW or AH). We will assess duplicate publications and companion papers of a trial together in order to evaluate all available data simultaneously (maximize data extraction, correct bias assessment). Cost and recourse data, if available, will be extracted, but not analyzed. we will approach the authors of the trials to specify any of the following data, had they not been reported sufficiently in the publication:


Trial characteristics

Bias risks components (as defined below); trial design (parallel, factorial, or crossover); number of intervention arms; length of follow-up; estimation of sample size; use of intention-to-treat analysis; relevant inclusion and exclusion criteria.


Participant characteristics and diagnosis

Baseline characteristics:number of participants; age range (mean or median) and sex ratio; type of CHD (acute or chronic); presence of cardiovascular risk factors (i.e. diabetes mellitus, hypertension, hyperlipidaemia, or smoking); method for,detection and presence of antibodies for C. pneumoniae, H. pylori, and cytomegalovirus.


Intervention characteristics

Type of antibiotics; dose of intervention; duration of therapy; mode of administration; type and dose of collateral intervention(s).


Outcome measures

All outcome measures will be extracted from each randomized clinical trial, and harms from non-randomized studies, and we will identify incomplete outcomes and selective outcome reporting.


Assessment of risk of bias in included studies

There is a risk of overestimation of beneficial intervention effects in randomized trials with unclear or inadequate methodological quality (Schulz 1995; Jadad 1996; Moher 1998; Jüni 2001; Kjaergard 2001). We will asses the influence of risk of bias on the results by evaluation of the following domains ( Table 1):

  • allocation sequence generation;
  • allocation sequence concealment;
  • blinding (participants, personal and outcome assessors);
  • complete outcome data reporting;
  • selective outcome reporting; and
  • other apparent biases (threats to validity).

The risk of bias in the included studies will be assessed as ether "low", "high" or "unclear" according to the criteria in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).


Assessment of reporting biases

Potential existence of bias will be addressed by funnel plots (Egger 1997), both visual and subsequent appropriate test for funnel plot asymmetry, according to the recommendations by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).


Unit of analysis issues

Unit of analysis is randomized trials. For trials using cluster randomization, if data is presented without proper control for clustering we will try to obtain individual patient data. If there is insufficient information to control for clustering, the unit of analysis used will be the cluster (Higgins 2011), and bias in this approach will be examined with sensitivity analysis. For trials using crossover design, only data from the first period will be included (Elbourne 2002; Higgins 2011). This in order to minimize any possibility of carry-over effect.


Data synthesis

Statistical analysis will be performed using the Cochrane Collaboration's statistical software, Review Manager (Review Manager 2012), and the software Trial Sequential Analysis (TSA 2011). Meta-analysis will be performed according to the intention-to-treat principle using the last reported observed response (carry forward). Binary outcomes will be expressed as relative risks (risk ratios, RRs) and 95% confidence intervals (CIs). Continuous outcomes will be analyzed using the differences in means or standardized mean difference (SMD).

For the assessment of harms, we will include and present non-randomized studies separately. Potential biases are expected to be greater for non-randomized studies, as well as heterogeneity due to different study designs for a combined analysis.

A random-effects and a fixed-effect model will be used (DerSimonian 1986; DeMets 1987). If both analyses show similar results, the random-effect model will be presented. Rare events will be estimated by Peto odds ratio (Deeks 1999). Should a meta-analysis not be possible, or inappropriate we will aim for a narrative assessment.

We will perform trial sequential analysis (TSA) on the primary outcomes. It calculates a diversity adjusted required information size, reduce the risk of random error and prevent premature statement of superiority of either experimental or control intervention (Brok 2008; Wetterslev 2008; Wetterslev 2009; Thorlund 2011). We will assume a type I error of 5%, type II error of 20%, event proportion as estimated in the control group (CEP) of all trials, and an anticipated number needed to treat (NNT) or number needed to harm (NNH) of 200 (for all-cause mortality and cardiovascular death ). As the CEP is a priori very uncertain we use the NNT or NNH as our a priori intervention effect anticipations in the TSA's allowing for quite different relative risk reductions or increase pending the CEP. Further, we will assume a type I error of 5%, type II error of 20%, CEP of all trials, as estimated in the traditional meta-analysis, and number needed to harm of 100 (for number of serious adverse events). We will perform sensitivity analysis in which the estimated required information size will be based upon the highest and lowest possible anticipated intervention effect and I2 from the 95% confidence intervals of the traditional meta-analysis intervention effect and I2, as well as the point estimate of these parameters.


Subgroup analysis and investigation of heterogeneity


Subgroup analysis

Subgroup analysis will be performed analyzing the primary outcomes (all-cause mortality and cardiovascular death) according to methodological quality (high risk of bias or low risk of bias), class of antibiotic, form of CHD (acute or chronic), antibody status, and duration of treatment.



Heterogeneity will be identified by visual inspection of the forest plots, using Chi2 test and a significance level of 0.1 (this test has low power when studies have small sample size, or are few in number), as well as I2 statistics with levels over 50% indicating substantial level of heterogeneity (Higgins 2011). In case significant heterogeneity will be found, the potential reason for it will be explored by performing sensitivity analysis. For the adjustment of the estimation of required information size we will apply the heterogeneity measure D2 as the intuitively obvious adjustment with I2 underestimate information size estimation (Wetterslev 2009)



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Cochrane Heart Group is thanked for their expert assistance in creating the search strategy.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Appendix 1. Search strategy



1 exp Coronary Disease/
2 exp Myocardial Ischemia/
3 (MYOCARD* adj3 INFARCT*).tw.
4 (CORONARY adj3 DISEASE*).tw.
5 (MYOCARD* adj3 ISCHEMI*).tw.
6 (MYOCARD* adj3 ISCHAEM*).tw.
7 (ISCHEMIC adj3 HEART).tw.
8 (ISCHAEMIC adj3 HEART).tw.
9 exp Atherosclerosis/
11 ANGINA*.tw.
12 or/1-11
13 Anti-Bacterial Agents/
14 Penicillin*.tw.
15 cephalosporin*.tw.
16 carbapenem*.tw.
17 monobactam*.tw.
18 beta-lactam*.tw.
19 aminoglycaside*.tw.
20 macrolide*.tw.
21 clindamycin*.tw.
22 exp Penicillins/
23 exp lactams/ or beta-lactams/
24 exp Tetracyclines/
25 exp Aminoglycosides/
26 exp Macrolides/
27 exp Clindamycin/
28 exp Chloramphenicol/
29 Fusidic Acid/
30 Vancomycin/
31 Daptomycin/
32 exp Polymyxins/
33 (antibiotic* or anti-bacterial* or anti-infective*).tw.
34 or/13-33
35 12 and 34
36 randomized controlled
37 controlled clinical
38 randomized.ab.
39 placebo.ab.
40 drug therapy.fs.
41 randomly.ab.
42 trial.ab.
43 groups.ab.
44 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45 exp animals/ not
46 44 not 45
47 35 and 46


What's new

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support


11 May 2012New citation required and major changesAuthorship changed with new author and new contact person. The methods have been updated in line with more recent Collaboration guidelines.



  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Protocol first published: Issue 2, 2002


11 August 2008AmendedAuthorship changed with new author and new contact person.

12 June 2008AmendedConverted to new review format.


Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Maria Skoog drafted the protocol based on a previous version authored by Tea Monk-Hansen, Eva Prescot, Bodil Als-Nielsen, Asbjørn Hróbjartsson, Jørn Wetterslev and Christian Gluud.

Asbjørn Hróbjartsson, Jørn Wetterslev, Berit Grevstad and Christian Gluud amended the protocol.


Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Berit Grevstad, Asbjørn Hróbjartsson, and Jørn Wetterslev have no potential conflict of interest. Maria Skoog, and Christian Gluud are involved in a randomized trial (CLARICOR) in which the intervention drug (Klacid Uno®) and placebo were donated by Abbott. This systematic review is not supported by any pharmaceutical company.


Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Appendices
  7. What's new
  8. History
  9. Contributions of authors
  10. Declarations of interest
  11. Sources of support

Internal sources

  • Copenhagen Trial Unit, Denmark.


External sources

  • The 1991 Pharmacy Foundation, Denmark.
  • The Danish Medical Research Council, Denmark.


Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Acknowledgements
  7. Appendices
  8. What's new
  9. History
  10. Contributions of authors
  11. Declarations of interest
  12. Sources of support
  13. Additional references
Aceti 1996
  • Aceti A, Mazzacurati G, Amendolea M, Pennica A, Zechini B, Trappolini M, et al. Relation of C reactive protein to cardiovascular risk factors. H pylori and C pneumoniae infections may account for most acute coronary syndromes. BMJ 1996;313(7054):428-9.
Agen 1993
  • Agen C, Danesi R, Blandizzi C, Costa M, Stacchini B, Favini P, et al. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions 1993;38(1-2):85-90.
Anderson 1999
  • Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99(12):1540-7.
Andraws 2005
  • Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005;293(21):2641-7.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Dahlen 1995
  • Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995;114(2):165-74.
Danesh 1997
Danesh 1998
  • Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998;316(7138):1130-2.
Danesh 2000a
Danesh 2000b
Danesh 2002
  • Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thomson A, et al. Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. European Heart Journal 2002;23(5):371-5.
Deeks 1999
  • Deeks JJ, Bradburn MJ, Localio R, Berlin J. Much ado about nothing: meta-analysis for rare events [abstract]. Proceedings of 2nd symposium on systematic reviews: beyond the basics. 1999:23.
DeMets 1987
DerSimonian 1986
Egger 1997
  • Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
Elbourne 2002
  • Elbourne DR,  Altman DG,  Higgins JP,  Curtin F,  Worthington HV,  Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Fabricant 1978
Folsom 1998
  • Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998;98(9):845-50.
Gluud 2008
  • Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, et al. CLARICOR Trial Group. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111(4):280-7.
Gupta 1997
  • Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96(2):404-7.
Gurfinkel 1999
  • Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. European Heart Journal 1999;20(2):121-7.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
ICH-GCP 1997
  • ICH-GCP. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1997 CFR & ICH Guidelines. 1. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Jadad 1996
  • Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
Jespersen 2006
  • Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, et al. CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332(7532):22-7.
Ji 2012
Jüni 2001
Kazar 2005
  • Kazar J,  Kovacova E,  Koncova K,  Cvachova S,  Mongiellova V,  Lietava J,  et al. Chlamydia pneumoniae antibodies and markers of inflammation in patients with cardiovascular diseases. Bratislavské Lekárske Listy 2005;106(11):341-4.
Keus 2010
  • Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology 2010;10(90):1-14.
Kjaergard 2001
  • Kjaergard L-L, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
Kuo 1993
  • Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arteriosclerosis and Thrombosis 1993;13(10):1501-4.
Leinonen 1990
  • Leinonen M, Linnanmaki E, Mattila K, Nieminen MS, Valtonen V, Leirisalo-Repo M, et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microbial Pathogenesis 1990;9(1):67-73.
Lenzi 2006
  • Lenzi C,  Palazzuoli A,  Giordano N,  Alegente G,  Gonnelli C,  Campagna MS,  et al. H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World Journal of Gastroenterology 2006;12(48):7815-20.
Linnanmaki 1993
  • Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87(4):1130-4.
Melnick 1993
  • Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. American Journal of Medicine 1993;95(5):499-504.
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
Moher 2009
  • Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009 Oct;62(10):1006-12.
Muhlestein 1996
  • Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. Journal of the American College of Cardiology 1996;27(7):1555-61.
Neumann 2001
  • Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357(9274):2085-9.
Patel 1995
  • Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995;311(7007):711-4.
Ramirez 1996
  • Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Annals of Internal Medicine 1996;125(12):979-82.
Review Manager 2012
  • The Nordic Cochrane Centre, The Cochane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochane Collaboration, 2012.
Ridker 1999
  • Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;99(9):1161-4.
Roivainen 2000
  • Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101(3):252-7.
Romano Carratelli 2006
  • Romano Carratelli C,  Nuzzo I,  Cozzolino D,  Bentivoglio C,  Paolillo R,  Rizzo A. Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases. International Immunopharmacology 2006;6(5):848-53.
Saikku 1988
  • Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2(8618):983-6.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Shor 1992
  • Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. South African Medical Journal 1992;82(3):158-61.
Sinisalo 1998
  • Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjala M, Sundberg S, et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. The Journal of Antimicrobial Chemotherapy 1998;41(1):85-92.
Thom 1991
  • Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arteriosclerosis and Thrombosis 1991;11(3):547-51.
Thom 1992
  • Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268(1):68-72.
Thorlund 2011
  • Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLoS One 2011;6(10):e25491.
Torgano 1999
  • Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F, Bertinieri G, et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999;99(12):1555-9.
TSA 2011
  • Copenhagen Trial Unit. Trial Sequential Analysis. 0.9. Copenhagen: Copenhagen Trial Unit, 2011.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta analysis. Journal of Clinical Epidemiology 2008;61:64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
WHO 2004
  • Mackay J, Mensah G (editors). The Atlas of Heart Disease and Stroke. Geneva: World Health Organization, 2004.
WHO 2011
  • Mendis S, Puska P, Norrving B (editors). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization, 2011.